Boehringer Ingelheim has expanded its ophthalmology portfolio by entering a collaboration with Re-Vana Therapeutics to develop extended-release ocular therapies. The potential partnership, valued at up to $1 billion, aims to enhance treatment options for eye disorders. Complementing this, Viridian Therapeutics secured a $70 million upfront payment from Kissei Pharmaceutical for Japanese rights to thyroid eye disease candidates, positioning itself as a competitor to Amgen’s Tepezza in Japan.